HOME
>
臨床医学：内科
>
循環器一般
> 循環器臨床サピア　3　ICDとCRT-Dの臨床

循環器臨床サピア　3　ICDとCRT-Dの臨床

出版社：	中山書店
著者：	北風政史・金智隆／著
発行日：	2009-12-01
分野：	臨床医学：内科 > 循環器一般
ISBN：	9784521731636
シリーズ：	循環器臨床サピア
電子書籍版：	2009-12-01 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

13,200 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

ICD（植込み型除細動器），CRT-D（除細動器付き心室再同期療法）は，最近の約10年間に急速に普及した新しい循環器診療の機器である。本書はそれらがどのような症例に有効か，また，薬物との併用法など，ガイドラインに基づいた臨床の最新知識を多くの図・写真とともに解説した本格的なテキストである。

目次

循環器臨床サピア　3　ICDとCRT-Dの臨床

―目次―

1章　不整脈治療の変遷
2章　致死性不整脈を予知する
3章　ICD/CRT-Dの作動原理を知る
4章　ICD/CRT-Dの適応とガイドラインを知る
5章　ICD/CRT-Dの植込み手術をおこなう
6章　ICD/CRT-Dの植込み適応となる疾患を知る
7章　ICD/CRT-D植込み症例における治療・検査の
　　　問題点と留意点はなにか
8章　致死性不整脈のメガトライアルを解説する

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章不整脈治療の変遷

P.11 掲載の参考文献

1) Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo : The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991 ; 324 : 781-787.

2) The CASCADE Investigators. Randomized anti-arrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993 ; 72 : 280-287.

3) Buxton AE, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999 ; 337 : 1569-1575.

4) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.

5) Brugada P, Brugada J. Right bundle branch block, persisitent ST elevation and sudden cardiac death : A distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol 1992 ; 20 : 1391-1396.

6) Haissaguerre M, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008 ; 358 : 2016-2023.

2章致死性不整脈を予知する

P.18 掲載の参考文献

1) Brendorp B, et al. DIAMOND Study Group. Danish Investigations Of Arrhythmia and Mortality On Dofetilide : Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. Eur J Heart Fail 2002 ; 4 : 201-206.

2) Farrell TG, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991 ; 18 : 687-697.

3) Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology. Circulation 1996 ; 93 : 1043-1065.

P.21 掲載の参考文献

1) Goldberger JJ, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. J Am Coll Cardiol 2008 ; 52 : 1179-1199.

2) La Rovere MT, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998 ; 351 : 478-484.

P.29 掲載の参考文献

1) Rosenbaum DS, et al. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994 ; 330 : 235-241.

2) Rosenbaum DS, et al. Predicting sudden cardiac death from T wave alternans of the surface electrigram : Promise and pitfalls. J Cardiovasc Electrophysiol 1996 ; 7 : 1095-1111.

3) Bloomfield DM, et al. Interpretation and classification of microvolt T wave alternans tests. J Cardiovasc Electrophysiol 2002 ; 13 : 502-512.

4) Verrier RL, et al. Amburatory electrocardiogram-based tracking of T wave alternans in postmyocardial infarction patients to assess risk of cardiac arrest of arrhythmic death. J Cardiovasc Electrophysiol 2003 ; 14 : 705-711.

5) Ikeda T, et al. Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction : Results of a collaborative cohort study. J Am Coll Cardiol 2006 ; 48 : 2268-2274.

P.35 掲載の参考文献

1) Gomes JA. The signal averaged ECG : A historical perspective. In : Gomes JA (ed). Signal Averaged Electrocardiography : Concepts, Methods, and Applications. Dordecht, The Netherlands : Kluwer Academic Publishers ; 1993. pp. 3-10.

2) 池田隆徳 (分担). 加算平均心電図法. 村川裕二 (編). 新目でみる循環器病シリーズ 1「心電図」. 東京 : メジカルビュー社 ; 2005. pp. 174-187.

P.44 掲載の参考文献

1) Brugada J, et al. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003 ; 108 : 3092-3096.

2) Daubert JP, et al. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2006 ; 47 : 98-107.

3) Buxton AE, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999 ; 341 : 1882-1890.

4) Costantini O, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial : Strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol 2009 ; 53 : 471-479.

5) Henthorn RW, et al. A fourth criterion for transient entrainment : The electrogram equivalent of progressive fusion. Circulation 1988 ; 77 : 1003-1012.

6) Stevenson WG, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 1993 ; 88 : 1647-1670.

7) Hayashi M, et al. Novel mechanism of postinfarction ventricular tachycardia originating in surviving left posterior Purkinje fibers. Heart Rhythm 2006 ; 3 : 908-918.

8) Reddy VY, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007 ; 357 : 2657-2665.

9) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 ; 335 : 1933-1940.

10) Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006 ; 48 : e247-e346.

11) Buxton AE, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000 ; 342 : 1937-1945.

12) Buxton AE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease : An analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 2002 ; 106 : 2466-2472.

13) Tanno K, et al. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J 2005 ; 69 : 19-22.

P.52 掲載の参考文献

1) 今井優ほか. 心疾患運動療法現場における安全性について. 臨床運動療法研究会誌 2000 ; 2 : 23-27.

2) 村山正博. 運動中の心事故と安全対策-運動指導者マニュアル. 1993. pp. 23-28.

3) 野原隆司. 心室性不整脈と運動療法. Heart View 1999 ; 7 : 35-41.

4) Bigger JT, et al. The relationship among ventricular arrythmias, left ventricular dysfunction, and mortality in the 2years after myocardial infarction. Circulation 1984 ; 69 : 250-258.

5) Exercise Standards for Testing and Trainig : A statement for healthcare professionals from the American Heart Association. Circulation 2001 ; 104 : 1694-1740.

6) Davis JS, et al. Benefits of cardiac rehabilitation in patients with implantable cardioverterdefibrillator. Arch Phys Med Rehabil 2005 ; 86 : 1924-1928.

7) LaRovere MT, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ARASMI Investigators. Lancet 1998 ; 351 : 478-484.

P.58 掲載の参考文献

1) Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med 2008 ; 358 : 169-176.

2) Zhu ZI, Clancy CE. Genetic mutations and arrhythmia : Simulation from DNA to electrocardiogram. J Electrocardiol 2007 ; 40 : S47-S50.

3) Lehnart SE, et al. Inherited arrhythmias : A National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 2007 ; 116 : 2325-2345.

4) Tsai CT, et al. Molecular genetics of atrial fibrillation. J Am Coll Cardiol 2008 ; 52 : 241-250.

P.60 掲載の参考文献

1) Lazarus A. Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems : Analysis of a worldwide database. Pacing Clin Electrophysiol 2007 ; 30 : S2-S12.

2) Varma N, et al. Evaluation of efficacy and safety of remote monitoring for ICD follow-up. The TRUST trial. AHA Scientific Sessions 2008.

3) Poole JE, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008 ; 359 : 1009-1017.

3章 ICD / CRT - Dの作動原理を知る

P.70 掲載の参考文献

1) Kroll MW, et al. Present understanding of shock polarity for internal defibrillation : The obvious and non-obvious clinical implications. Pacing Clin Electrophysiol 2006 ; 29 : 885-891.

2) Gulizia MM, Piraino L, Andrea Grammatico on behalf of PITAGORA ICD Study Investigators. A Randomized Study to Compare Ramp Versus Burst Antitachycardia Pacing Therapies to Treat Fast Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter Defibrillators : The PITAGORA ICD Trial. Circ Arrhythmia Electrophysiol 2009 ; 2 : 146-153.

3) Sweeney MO, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients : Results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005 ; 111 : 2898-2905.

4) Kreuz J, et al. Incidence and characteristics of appropriate and inappropriate therapies in recipients of ICD implanted for primary prevention of sudden cardiac death. Pacing Clin Electrophysiol 2007 ; 30 (Suppl 1) : S125-127.

5) Yu CM, et al. Intrathoracic impedance monitoring in patients with heart failure : Correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005 ; 112 : 841-848.

P.73 掲載の参考文献

1) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 ; 335 : 1933-1940.

2) Buxton AE, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999 ; 341 : 1882-1890.

3) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

4) Kadish A, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 ; 350 : 2151-2158.

5) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.

6) The antiarrhythmics versus implantable defibrillators (AVID) investigators. A comparison of antiarrhythmicdrug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997 ; 337 : 1576-1583.

7) Kuck KH, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : The Cardiac Arrest Study Hamburg (CASH). Circulation 2000 ; 102 : 748-754.

8) Connolly SJ, et al. Canadian implantable defibrillator study (CIDS) : A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000 ; 101 : 1297-1302.

4章 ICD / CRT - Dの適応とガイドラインを知る

P.85 掲載の参考文献

1) ACC/AHA/HRS 2008 Guideline for Device-Based Therapy of Cardiac Rhythm Abnormality. Circulation 2008 ; 117 : e350-e408.

2) Moss AJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996 ; 335 : 1933-1940.

3) Moss AJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

4) Bristow MR, et al, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 ; 350 : 2140-2150.

P.92 掲載の参考文献

1) Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006 ; 48 : e247-e346.

1) Connolly SJ, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000 ; 21 : 2071-2078.

2) Wyse DG, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes : High risk for death in follow-up. J Am Coll Cardiol 2001 ; 38 : 1718-1724.

2) Wyse DG, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes : High risk for death in follow-up. J Am Coll Cardiol 2001 ; 38 : 1718-1724.

3) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

3) Epstein AE, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities : Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) : Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008 ; 117 : 2820-2840.

4) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 ; 335 : 1933-1940.

4) Hunt SA, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult? Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005 ; 46 : 1116-1143.

5) Goldberger JJ, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death : A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. J Am Coll Cardiol 2008 ; 52 : 1179-1199.

5) Buxton AE, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999 ; 341 : 1882-1890.

6) Buxton AE, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 2000 ; 342 : 1937-1945.

7) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.

8) Hohnloser SH, et al. The Defibrillator In Acute Myocardial Infarction Trial (DINAMIT) : Study protocol. Am Heart J 2000 ; 140 : 735-739.

9) Callans DJ. Patients with hemodynamically tolerated ventricular tachycardia require implantable cardioverter defibrillators. Circulation 2007 ; 116 : 1196-1203.

10) Mark E, Josephson ME. All patients with hemodynamically tolerated postinfarction ventricular tachycardia do not require an implantable cardioverter-defibrillator. Circulation 2007 ; 116 : 1204-1212.

11) Bokhari F, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone : eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004 ; 110 : 112-116.

12) Bansch D, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy : the Cardiomyopathy Trial (CAT). Circulation 2002 ; 105 : 1453-1458.

13) Bigger JT, et al. Mechanisms of death in the CABG Patch trial : A randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999 ; 99 : 1416-1421.

14) Brugada J, et al. Coronary artery revascularization in patients with sustained ventricular tachycardia in the chronic phase of myocardial infarction : Effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol 2001 ; 37 : 529-533.

15) Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997 ; 337 : 1569-1575.

16) Raitt MH, et al". Stable"ventricular tachycardia is not a benign rhythm : Insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. Circulation 2001 ; 103 : 244-252.

17) Connolly SJ, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000 ; 21 : 2071-2078.

18) Kadish A, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 ; 350 : 2151-2158.

19) Poole JE, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008 ; 359 : 1009-1017.

5章 ICD / CRT - Dの植込み手術を行う

P.104 掲載の参考文献

1) Leon AR, et al. MIRACLE Study Program. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure : Combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol 2005 ; 46 : 2348-2356.

P.111 掲載の参考文献

1) Kiviniemi MS, et al. Complications related to permanent pacemaker therapy. Pacing Clin Electrophysiol 1999 ; 22 : 711.

2) 石川利之ほか. 心房細動の発生および心房負荷から見たペーシング・モードの適応. 心臓ペーシング 1992 ; 8 : 455-459.

3) Ishikawa T, et al. Acute changes in left atrial and left ventricular diameters after physiological pacing. Pacing Clin Electrophysiol 1996 ; 19 : 143-149.

P.113 掲載の参考文献

1) Bleeker GB, et al. Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy : Analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation 2007 ; 116 : 1440-1448.

2) Suffoletto MS, et al. Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation 2006 ; 113 : 960-968.

3) Lim P, et al. Longitudinal strain delay index by speckle tracking imaging : A new marker of response to cardiac resynchronization therapy. Circulation 2008 ; 118 : 1130-1137.

4) Jansen AH, et al. Qualitative observation of left ventricular multiphasic septal motion and septal-to-lateral apical shuffle predicts left ventricular reverse remodeling after cardiac resynchronization therapy. Am J Cardiol 2007 ; 99 : 966-969.

5) Chung ES, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008 ; 117 : 2608-2616.

6章 ICD / CRT - Dの植込み適応となる疾患を知る

P.128 掲載の参考文献

1) Sohn DW, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997 ; 30 : 474-480.

2) The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987 ; 316 : 1429-1435.

3) The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 ; 325 : 293-302.

4) Pitt B, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997 ; 349 : 747-752.

5) Cohn JN, et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2002 ; 345 : 1667-1675.

6) Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 2003 ; 362 : 754-755.

7) McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet 2003 ; 362 : 767-771.

8) Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999 ; 341 : 709-717.

9) Goldstein S, et al. Clinical studies on beta blockers and heart failure preceding the MERITHF Trial. Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. Am J Cardiol 1997 ; 80 : 50J-53J.

10) Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 ; 344 : 1651-1658.

11) Hori M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure : The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004 ; 147 : 324-330.

12) Abraham WT, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002 ; 346 : 1845-1853.

13) Cleland JG, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 ; 352 : 1539-1549.

14) Domanski MJ, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999 ; 34 : 1090-1095.

15) Kadish A, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 ; 350 : 2151-2158.

16) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.

17) Bristow MR, et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 ; 350 : 2140-2150.

18) Moss AJ, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009 ; 361 : 1329-1338.

P.136 掲載の参考文献

1) Epstein AE, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) ; American Association for Thoracic Surgery ; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) : Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008 ; 117 : e350-408.

2) Sutton MG, et al. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology : Quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation 2006 ; 113 : 266-272.

3) Gasparini M, et al. Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy : Temporal pattern and clinical predictors. Am Heart J 2008 ; 155 : 507-514.

4) Bleeker GB, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 2006 ; 113 : 969-976.

5) Moss AJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

6) Shiga T, et al. Heart Institute of Japan Acute Myocardial Infarction-II (HIJAMI-II) Investigators. Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era : Results from the HIJAMI-II registry. Heart 2009 ; 95 : 216-220.

P.144 掲載の参考文献

1) Fananapazir L, et al. Prognostic determinants in hypertrophic cardiomyopathy : Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Curculation 1992 ; 86 : 730-740.

2) Fananapazir L, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy : A consecutive analysis in 155 patients. Circulation 1989 ; 80 : 1259-1268.

3) Zipes DP, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol 2006 ; 48 : e247-346.

4) Maron BJ, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007 ; 298 : 405-412.

5) Maron BJ, et al. American Colledge of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American Colledge of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003 ; 42 : 1687-1713.

P.157 掲載の参考文献

1) Maron BJ, et al. Contemporary definitions and classification of the cardiomyopathies : An AHA Scientific Statement From the Council on Clinical Cardiology, Heart Failure and Transplantation Committee ; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups ; and Council on Epidemiology and Prevention. Circulation 2006 ; 113 : 1807-1816.

2) Hiraga H, et al. Guideline for Diagnosis of Cardiac Sarcoidosis : Study Report on Diffuse Pulmonary Disease. 1993. pp. 23-24.

3) 関口守衛ほか. 心筋生検. 日本循環器学会専門医誌循環器専門医 1999 ; 7 : 363-375.

4) 日本サルコイドーシス/肉芽腫性疾患学会. サルコイドーシスの診断基準と診断の手引き-2006 要約. サルコイドーシス/肉芽腫性疾患 2006 ; 26 : 77-82. http://www.jssog.com/papers/2006-15.pdf

5) Uemura A, et al. Histologic diagnostic rate of cardiac sarcoidosis : Evaluation of endocardial biopsies. Am Heart J 1999 ; 138 : 299-302.

6) Iannuzzi MC, et al. Sarcoidosis. N Engl J Med 2007 ; 357 : 2153-2165.

7) Ishimaru S, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005 ; 26 : 1538-1543.

8) 竹端均, 和泉徹. アルコール性心筋症. 日本臨床別冊循環器症候群 (第2版). 2008. pp. 7-10.

P.167 掲載の参考文献

1) Arthur AM, et al. Proposed diagnostic criteria for the Brugada syndrome : Consensus report. Circulation 2002 ; 106 : 2514-2519.

2) 鎌倉史郎. Brugada 症候群を疑ったときの対応. 日本内科学会雑誌. 2006 ; 95 : 320-327.

3) Antzelevitch C, et al. Brugada Syndrome : Report of the second consensus conference : Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005 ; 111 : 659-670.

4) Priori SG, et al. Natural history of Brugada syndrome : Insights for risk stratification and management. Circulation 2002 ; 105 : 1342-1347.

5) Atarashi H, et al. Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads : Japanese Registry of Brugada Syndrome. Idiopathic Ventricular Fibrillation lnvestigators. J Am Coll Cardiol 2001 : 37 ; 1916-1920.

6) Takagi M, et al. Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with Brugada syndrome : Multicenter study in Japan. J Cardiovasc Electrophysiol 2007 ; 18 : 1244-1251.

7) Sacher F, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome : A multicenter study. Circulation 2006 ; 114 ; 2317-2324.

P.175 掲載の参考文献

1) Corrado D, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy : Need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation 2000 ; 101 : E101-106.

2) McKenna WJ, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994 ; 71 : 215-218.

3) 大江透. 不整脈ベッドサイド診断から非薬物治療まで. 東京 : 医学書院 ; 2007.

4) Buja G, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia : Risk stratification and therapy. Prog Cardiovasc Dis 2008 ; 50 : 282-293.

5) Basso C, et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet 2009 ; 373 : 1289-1300.

P.183 掲載の参考文献

1) Schwartz PJ, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993 ; 88 : 782-784.

2) Priori SG, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003 ; 348 : 1866-1874.

3) Yan GX, et al. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 1998 ; 98 : 1921-1927.

4) ACC/AHA/HRS 2008 Guidelines for Device Based Therapy of Cardiac Rhythm Abnormalities : Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol 2008 ; 51 : 2085-2105.

P.191 掲載の参考文献

1) Leenhardt A, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995 ; 91 : 1512-1519.

1) Ito S, et al. Bidirectional ventricular tachycardia. J Cardiovasc Electrophysiol 2002 ; 13 : 1312.

1) Pizzale S, et al. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2008 ; 19 : 1319-1321.

2) Sumitomo N, et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J 2007 ; 71 : 1606-1609.

2) Priori SG, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002 ; 106 : 69-74.

2) Wilde AA, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008 ; 358 : 2024-2029.

3) Collura CA, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 2009 ; 6 : 752-759.

3) Bauce B, et al. Screening for ryanodine receptor type 2 mutations in families with effortinduced polymorphic ventricular arrhythmias and sudden death : Early diagnosis of asymptomatic carriers. J Am Coll Cardiol 2002 ; 40 : 341-349.

3) Sumitomo N, et al. Catecholaminergic polymorphic ventricular tachycardia : Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003 ; 89 : 66-70.

4) Mohamed U, et al. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2007 ; 18 : 791-797.

4) Mohamed U, et al. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 2006 ; 3 : 1486-1489.

5) Rosso R, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007 ; 4 : 1149-1154.

5) Liu N, et al. Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis 2008 ; 51 : 23-30.

6) Katz G, et al. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond. Curr Probl Cardiol 2009 ; 34 : 9-43.

6) Sansone V, Tawil R. Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 2007 ; 4 : 233-237.

7) Haruna Y, et al. Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome. Hum Mutat 2007 ; 28 : 208.

8) Zhang L, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations : Characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 2005 ; 111 : 2720-2726.

P.199 掲載の参考文献

1) Gasparini M, et al. Inferior vena cava loop of the implantable cardioverter defibrillator endocardial ead : A possible solution ot the growth problem in pediatric implantation. Pacing Clin Electrophysiol 2000 ; 23 : 2108-2112.

2) Kantoch MJ, et al. Direct intracardiac placement of an automatic implantable cardioverter defibrillator coil lead in a small child. Europace 2007 ; 9 : 669-671.

3) Luedemann M, et al. Implantable cardioverter defibrillator in a child using single subcutaneous array lead and an abdominal active can. Pacing Clin Electrophysiol 2004 ; 27 : 117-119.

4) Cannon BC, et al. Innovative techniques for placement of implantable cardioverter-defibrillator leads in patients with limited venous access to the heart. Pacing Clin Electrophysiol 2006 ; 29 : 181-187.

5) Bauersfeld U, et al. Initial experience with implantable cardioverter defibrillator systems using epicardial and pleural electrodes in pediatric patients. Ann Thorac Surg 2007 ; 84 : 303-305.

6) Kiesewetter C, et al. Left ventricular dysfunction after cardiac resynchronization therapy in congenital heart disease patients with a failing systemic right ventricle. Pacing Clin Electrophysiol 2008 ; 31 : 159-162.

7) Jauvert G, et al. Effects of cardiac resynchronization therapy on echocardiographic indices, functional capacity, and clinical outcomes of patients with a systemic right ventricle. Europace 2009 ; 11 : 184-190.

8) Uemura H, et al. Surgical anatomy of the coronary circulation in hearts with discordant atrioventricular connections. Eur J Cardiothorac Surg 1996 ; 10 : 194-200.

P.205 掲載の参考文献

1) 厚生労働科学研究 (主任研究者 : 坂上正道) (編). 乳幼児突然死症候群 (SIDS) の診断のためのガイドライン. 厚生労働科学研究 (子ども家庭総合研究事業) : 乳幼児突然死症候群 (SIDS) の診断のためのガイドライン作成およびその予防と発症率軽減に関する研究, 平成14年度～16年度総合研究報告書. 2005. pp. 23-26.

2) Schwartz PJ, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998 ; 338 : 1709-1714.

3) Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol 2007 ; 49 : 240-246. Epub 2006 Dec 29.

4) Miller TE, et al. Recurrent third-trimester fetal loss and maternal mosaicism for long-QT syndrome. Circulation 2004 ; 109 : 3029-3034.

5) Tuzcu V. Resolution of T-wave oversensing with implantable cardioverter defibrillator generator replacement in an adolescent. Pacing Clin Electrophysiol 2007 ; 30 : 929-932.

P.207 掲載の参考文献

1) Bayes de Luna A, et al. Ambulatory sudden cardiac death : Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989 ; 117 : 151-159.

2) Stiell IG, et al. Advanced cardiac life support in out-ofhospital cardiac arrest. N Engl J Med 2004 ; 351 : 647-656.

3) White RD, et al. Evolution of a community-wide early defibrillation programme experience over 13 years using police/fire personnel and paramedics as responders. Resuscitation 2005 ; 65 : 279-283.

4) 日本版救急蘇生ガイドライン策定小委員会 (編). 改定3版救急蘇生法の指診2005 医療従事者用. 東京 : へるす出版 ; 2007. pp. 7-28.

5) 特定非営利活動法人大阪ライフサポート協会 (編). 写真と動画でわかる一次救命処置. 東京 : 学習研究社 ; 2007. pp. 82-84.

6) 西本泰久ほか. ペースメーカー装着患者における心肺蘇生法の問題点. 日本臨床救急医学会雑誌 2000 ; 3 : 244-250.

7) 日本版救急蘇生ガイドライン策定小委員会 (編). 改定3版救急蘇生法の指診2005 市民用. 東京 : へるす出版 ; 2006. p. 8.

7章 ICD / CRT - D植込み症例における治療・検査の問題点と留意点はなにか

P.218 掲載の参考文献

1) Hynes DL, Friedman PA. Implantation-related complications. In : Hynes DL, Friedman PA (editors). Cardiac pacing, defibrillation and resynchronization. A clinical approach. West Sussex : Wiley-Blackwell ; 2008. pp. 202-233

2) Jansen AH, et al. Qualitative observation of left ventricular multiphasic septal motion and septal-to-lateral apical shuffle motion predicts left ventricular reserve remodeling after cardiac resynchronization therapy. Am J Cardiol 2007 ; 99 : 966-969.

3) Penicka M, et al. Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation 2004 ; 109 : 978-983.

4) Suffoletto MS, et al. Novel speckled-tracking radial strain from routine black-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation 2006 ; 113 : 960-968.

5) Yu CM, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002 ; 105 : 438-445.

P.228 掲載の参考文献

1) Lucignani G. Metaiodobenzylguanidine (mIBG) molecular imaging in implantable cardioverter defibrillator (ICD) therapy planning : A health technology assessment issue. Eur J Nucl Med Mol Imaging 2009 ; 36 : 1346-1350.

2) Bax JJ, et al. Cardiac resynchronization therapy : Part 1 ─ issues before device implantation. J Am Coll Cardiol 2005 ; 46 : 2153-2167.

3) Yu CM, et al. Echocardiographic evaluation of cardiac dyssynchrony for predicting a favorable response to cardiac resynchronization therapy. Heart 2004 ; 90 (Suppl. IV) : iv 17-22.

4) Bax JJ, et al. Left ventricular dissynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004 ; 44 : 1834-1840.

5) Yu CM, et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation 2004 ; 110 : 66-73.

6) Chung ES, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008 ; 117 : 2608-2616.

7) O'Connell JW, et al. A unique method by which to quantitate synchrony with equilibrium radionuclide angiography. J Nucl Cardiol 2005 ; 12 : 441-450.

8) Henneman MM, et al. Phase analysis of gated myocardial perfusion single-photon emission computed tomography compared with tissue Doppler imaging for the assessment of left ventricular dissynchrony. J Am Coll Cardiol 2007 ; 49 : 1708-1714.

9) Chen J, et al. Assessment of left ventricular mechanical dyssynchrony by phase analysis of ECG-gated SPECT myocardial perfusion imaging. J Nucl Cardiol 2008 ; 15 : 127-136.

10) Kiso K, et al. Quantitative assessment of LV regional dyssynchrony by ECG-gated myocardial perfusion SPECT for the management of cardiac resynchronization therapy compared with echocardiographic tissue synchronization imaging. J Nucl Med 2008 ; 49 (Suppl. 1) : 1P.

P.232 掲載の参考文献

1) McCollough CH, et al. Effects of CT irradiation on implantable cardiac rhythm management devices. Radiology 2007 ; 243 : 766-774.

2) 平成17年11月25日付薬食安発第1125001号安全対策課長通知.

3) Nazarian S, et al. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1. 5 tesla. Circulation 2006 ; 114 : 1277-1284.

4) Gimbel JR, et al. Outcome of magnetic resonance imaging (MRI) in selected patients with implantable cardioverter defibrillators (ICDs). Pacing Clin Electrophysiol 2005 ; 28 : 270-273.

5) Fiek M, et al. Complete loss of ICD programmability after magnetic resonance imaging. Pacing Clin Electrophysiol 2004 ; 27 : 1002-1004.

6) Faris OP, et al. Food and Drug Administration perspective : Magnetic resonance imaging of pacemaker and implantable cardioverter-defibrillator patients. Circulation 2006 ; 114 : 1232-1233.

P.242 掲載の参考文献

1) Ho AT, et al. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. PACE 2005 ; 28 : 647-653.

2) Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) : Randomised controlled trial. Lancet 2003 ; 362 : 7-13.

3) McMurray J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction : Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005 ; 45 : 525-530.

4) McKenna WJ, et al. Hypertrophic cardiomyopathy : management, risk stratification, and prevention of sudden death. Heart 2002 ; 87 : 169-176.

5) Connolly SJ, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators : the OPTIC Study : A randomized trial. JAMA 2006 ; 295 : 165-171.

6) Singh BN, et al. Miodarone versus sotalol for atrial fibrillation. N Engl J Med 2005 ; 352 : 1861-1872.

7) AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation : an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003 ; 42 : 30-32.

8) Hohnloser SH, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold : the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006 ; 114 : 104-109.

9) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary. Circulation 2006 ; 114 : 1088-1132.

10) Cohn JN, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chromic congestive heart failure. N Engl J Med 1991 ; 325 : 303-310.

11) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 ; 316 : 1429-1435.

12) Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991 ; 325 : 293-302.

13) Domanski MJ, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. JACC 1999 ; 33 : 598-604.

14) Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular disfunction after myocardial infarction. N Engl J Med 2003 ; 348 : 1309-1321.

15) The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997 ; 336 : 525-533.

16) Lubsen J, et al. Effect of pimobendan on exercise capacity in patients with heart failure : main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996 ; 76 : 223-231.

17) Kjekshus J, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 ; 357 : 2248-2261.

18) Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) : A randomized, double-blind, placebo-controlled trial. Lancet 2008 ; 372 : 1231-1239.

19) Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial) : A randomised, double-blind, placebo-controlled trial. Lancet 2008 ; 372 : 1223-1230.

P.250 掲載の参考文献

1) Wannamethee SG, et al. Physical activity and mortality in older men with diagnosed coronary heart disease. Circulation 2000 ; 102 : 1358-1363.

2) Myers J, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002 ; 346 : 793-801.

3) Cohen-Solal A, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure : Relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999 ; 33 : 759-766.

4) Belardinelli R, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure : Effects on functional capacity, quality of life, and clinical outcome. Circulation 1999 ; 99 : 1173-1182.

5) Davids JS, et al. Benefits of cardiac rehabilitation in patients with implantable cardioverterdefibrillators : A patient survey. Arch Phys Med Rehabil 2005 ; 86 : 1924-1928.

P.254 掲載の参考文献

1) HaIssaguerre M, et al. Spontaneous initiation of atrial fi brillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 ; 339 : 659-66.

2) Khan MN, et al. Pulmonary-vein isolation for atrial fi brillation in patients with heart failure. N Engl J Med 2008 ; 359 : 1778-1785.

3) Gasparini M, et al. Long-term survival in patients undergoing cardiac resynchronization therapy : The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fi brillation. Eur Heart J 2008 ; 29 : 1644-1652.

4) Wood MA, et al. Clinical outcomes after ablation and pacing therapy for atrial fi brillation : A meta-analysis. Circulation 2000 ; 101 : 1138-1144.

5) Soejima K, et al. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy : The importance of low-voltage scars. J Am Coll Cardiol 2004 ; 43 : 1834-1842.

P.256 掲載の参考文献

1) 西本泰久. ペースメーカー装着患者における心肺蘇生法の問題点. 日臨救医誌 2000 ; 3 : 244-250.

2) 家坂義人. 心臓ペースメーカーに関する基礎的研究 DC通電の影響. 心臓 1979 ; 11 : 1127-1131.

P.258 掲載の参考文献

1) 総務省 : 電波の医療機器への影響に関する調査結果. 平成18年5月 (http://www.soumu.go.jp/s-news/2006/060530_1.html).

2) 総務省 : 電波の医療機器への影響に関する調査結果. 平成19年4月 (http://www.soumu.go.jp/s-news/2007/070424_5.html).

3) 三井利夫ほか. 不整脈に起因する失神例の運転免許取得に関する診断書作成と適性検査施行の合同検討委員会ステートメント. 不整脈 2003 ; 19 : 502-512.

8章致死性不整脈のメガトライアルを解説する

P.265 掲載の参考文献

1) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 ; 335 : 1933-1940.

2) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

3) Epstein AP, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities : Executive Summary : A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) : Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008 ; 117 ; 2820-2840.

4) Zwanziger J, et al. The cost effectiveness of implantable cardioverter-defibrillators : Results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT) -II. J Am Coll Cardiol 2006 ; 47 : 2310-2318.

P.272 掲載の参考文献

1) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996 ; 335 : 1933-1940.

2) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

3) Hohnloser SH, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004 ; 351 : 2481-2488.

4) Myerburg RJ. Implantable cardioverter-defibrillator after myocardial infarction. N Engl J Med 2008 ; 359 : 2245-2253.

5) Wilber DJ, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004 ; 109 : 1082-1084.

P.280 掲載の参考文献

1) Kadish A, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 ; 350 : 2151-2158.

2) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996 ; 335 : 1933-1940.

3) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

4) Bansch D, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy : The cardiomyopathy trial (CAT). Circulation 2002 ; 105 : 1453-1458.

5) Strickberger SA, et al. Amiodarone versus implantable cardioverter-defibrillator : Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003 ; 41 : 1707-1712.

6) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.

7) Kadish A, et al. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol 2006 ; 47 : 2477-2482.

8) Ellenbogen KA, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006 ; 113 : 776-782.

P.286 掲載の参考文献

1) Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237.

2) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

3) Strickberger SA, et al. Amiodarone versus implantable cardioverter-defibrillator : Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003 ; 41 : 1707-1712.

4) Kadish A, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 ; 350 : 2151-2158.

5) Hammill SC, et al. Review of the registry's first year, data collected, and future plans. Heart Rhythm 2007 ; 4 : 1260-1263.

6) 清水昭彦ほか. 心不全と心室頻拍-我が国の心不全患者におけるICD/CRT-D植込みの実態と適応の変遷. Journal of Arrhythmia 2009 ; (245) : 105.

P.290 掲載の参考文献

1) Buxton AE, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999 ; 341 : 1882-1890.

2) Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996 ; 355 : 1933-1940.

3) Epstein AE, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation 2008 ; 117 ; e350-e408.

4) Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883.

P.292 掲載の参考文献

1) Buxton AE, et al. MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease : Lessons from the MUSTT study. J Am Coll Cardiol 2007 ; 50 : 1150-1157.

2) Poole JE, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008 ; 359 : 1009-1017.

3) http://www.heartrhythmondemand.org/heartrhythm2009/SP117552/play/?prd=090502-SP11-7552&prn=SP11.7552

書評

書評を投稿する

最近チェックした商品履歴

Loading...